Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D S Tan

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
International Journal of Cancer|March 17, 2000
Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breastA C Leong, A M Hanby, H W Potts, et al.
British Journal of Cancer|April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursT A Yap, H Cortes-Funes, H Shaw, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2015
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignanciesA L Wong, R A Soo, D S Tan, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
International Journal of Cancer|March 17, 2000
Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breastA C Leong, A M Hanby, H W Potts, et al.
British Journal of Cancer|April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursT A Yap, H Cortes-Funes, H Shaw, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2015
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignanciesA L Wong, R A Soo, D S Tan, et al.
Pageof 5